The Absolute Effect / Evidence / EORTC 22863
Prostate Cancer · Radiation · High-risk / locally advanced
EORTC 22863
Clinical question
Does adding long-term androgen deprivation to definitive radiotherapy improve survival in high-risk or locally advanced prostate cancer?
Trial context
Population
415 men
Intervention
RT 50 Gy pelvis + 20 Gy prostate boost; 3 years ADT (cyproterone then goserelin)
Comparator
RT alone
Primary / key evidence
10-y OS 58% vs 40%; absolute +18 pp; p=0.0004. 10-y disease-free survival 48% vs 23%; +25 pp.
Absolute Effect
What changes for patients?
10-y OS 58% vs 40%; absolute +18 pp; p=0.0004. 10-y disease-free survival 48% vs 23%; +25 pp.
NNT/NNH: Not calculated unless a defensible fixed-time event-rate comparison was available in the cited primary analysis; median-survival differences alone are not converted to NNT.
Clinical interpretation
Long-term ADT established a survival benefit when added to definitive RT in this high-risk population.
Limitations / maturity
Interpret the effect in the context of the trial population, endpoint definition, follow-up and treatment era. Subsequent trials and evolving standards may limit direct applicability to contemporary patients.
Primary publication
Bolla M et al. EORTC 22863; long-term analysis.